

South & Central America Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis

Market Report | 2023-01-10 | 132 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The South & Central America influenza vaccines market is expected to grow from US\$ 497.54 million in 2022 to US\$ 736.35 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

Increase in Government Support to Promote Influenza Vaccination

The governing bodies of various states and countries are supporting the promotion of vaccination through multiple activities and programs. By 2022, enough vaccines have been secured to cover all risk groups eligible for a government-funded flu vaccine through the NIP.

Below are a few more instances supporting the government support for influenza vaccination: In Oct 2021, with flu season approaching, the Provincial Government was encouraging all Newfoundlanders and Labradorians to get a flu shot in the year 2021. Starting October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. People can also get the vaccine through their family doctor or local pharmacy. Thus, increasing government support to promote influenza vaccination is driving the South & Central America influenza vaccines market.

Market Overview

The South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market for influenza vaccines in the region is expected to experience growth opportunities during the forecast period. The influenza vaccines market in SAM is expected to grow owing to factors such as an increase in cases of influenza in the region, surge in various research activities in the region, rise in health awareness, and an increase in healthcare expenditure by the countries of the region.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

South & Central America Influenza Vaccines Market Segmentation

The South & Central America influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the South & Central America influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the South & Central America influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the South & Central America influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the South & Central America influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the South & Central America influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the South & Central America influenza vaccines market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.

AstraZeneca; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the South & Central America influenza vaccines market.

Table of Contents:

TABLE OF CONTENTS

1. Introduction
 - 1.1 Study Scope
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 South & Central America Influenza Vaccines Market - By Vaccine Type
 - 1.3.2 South & Central America Influenza Vaccines Market - By Virus Type
 - 1.3.3 South & Central America Influenza Vaccines Market - By Technology
 - 1.3.4 South & Central America Influenza Vaccines Market - By Route of Administration
 - 1.3.5 South & Central America Influenza Vaccines Market - By Target Group
 - 1.3.6 South & Central America Influenza Vaccines Market - By Country
2. South & Central America Influenza Vaccines Market - Key Takeaways
3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
4. South & Central America Influenza Vaccines Market - Market Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1 Overview
- 4.2 PEST Analysis
 - 4.2.1 South and Central America PEST Analysis
- 4.3 Experts Opinion
- 5. South & Central America Influenza Vaccines Market - Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Increase in Government Support to Promote Influenza Vaccination
 - 5.1.2 Increasing Investment by Top Market Players and Governments
 - 5.2 Market Restraints
 - 5.2.1 High Cost of Vaccine Development
 - 5.3 Market Opportunities
 - 5.3.1 Emerging Economies
 - 5.4 Future Trends
 - 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
 - 5.5 Impact Analysis
- 6. Influenza Vaccine Market - South & Central America Analysis
 - 6.1 South & Central America Influenza Vaccines Market, By Country - Forecasts And Analysis
 - 6.2 South & Central America Influenza Vaccines Market Revenue Forecasts And Analysis
 - 6.2.1 South & Central America : Influenza Vaccines Market, 2019-2028 (US\$ Million)
- 7. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type
 - 7.1 Overview
 - 7.2 South & Central America Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
 - 7.2.1 South and Central America: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
 - 7.3 Quadrivalent Vaccines
 - 7.3.1 Overview
 - 7.3.2 Quadrivalent Vaccines : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 7.4 Trivalent Vaccines
 - 7.4.1 Overview
 - 7.4.2 Trivalent Vaccines : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 8. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type
 - 8.1 Overview
 - 8.2 South & Central America Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
 - 8.2.1 South and Central America: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
 - 8.3 Influenza Virus Type A
 - 8.3.1 Overview
 - 8.3.2 Influenza Virus Type A : Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 8.4 Influenza Virus Type B
 - 8.4.1 Overview
 - 8.4.2 Influenza Virus Type B : Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology
 - 9.1 Overview
 - 9.2 South & Central America Influenza Vaccines Market, By Technology 2022 & 2028 (%)
 - 9.2.1 South and Central America: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
 - 9.3 Egg-based
 - 9.3.1 Overview
 - 9.3.2 Egg-based : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
 - 9.4 Cell-based

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.1 Overview
- 9.4.2 Cell-Based : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 10. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration
- 10.1 Overview
- 10.2 South & Central America Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
- 10.3 Injection
- 10.3.1 Overview
- 10.3.2 Injection : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 10.4 Nasal Spray
- 10.4.1 Overview
- 10.4.2 Nasal Spray: South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - By Target Group
- 11.1 Overview
- 11.2 South & Central America Influenza Vaccines Market, By Target Group 2022 & 2028 (%)
- 11.2.1 South and Central America: Influenza Vaccines Market, by Target Group, 2019-2028 (US\$ Million)
- 11.3 Infants
- 11.3.1 Overview
- 11.3.2 Infants : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.4 Children
- 11.4.1 Overview
- 11.4.2 Children: South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.5 Adults
- 11.5.1 Overview
- 11.5.2 Adults : South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.6 Elderly People
- 11.6.1 Overview
- 11.6.2 Elderly People: South & Central America Influenza Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 12. South & Central America Influenza Vaccines Market Analysis and Forecasts To 2028 - Country Analysis
- 12.1 South and Central America Influenza Vaccine Market Revenue and Forecasts To 2028
- 12.1.1 Overview
- 12.1.3 South and Central America: Influenza Vaccine Market, by Country, 2022 & 2028 (%)
- 12.1.3.1 Brazil: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
- 12.1.3.1.1 Overview
- 12.1.3.1.2 Brazil: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
- 12.1.3.1.3 Brazil: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 12.1.3.1.4 Brazil: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
- 12.1.3.1.5 Brazil: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
- 12.1.3.1.6 Brazil: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
- 12.1.3.1.7 Brazil: Influenza Vaccines Market, by Target Group, 2019-2028 (US\$ Million)
- 12.1.3.2 Argentina: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
- 12.1.3.2.1 Overview
- 12.1.3.2.2 Argentina: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
- 12.1.3.2.3 Argentina: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
- 12.1.3.2.4 Argentina: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
- 12.1.3.2.5 Argentina: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
- 12.1.3.2.6 Argentina: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
- 12.1.3.2.7 Argentina: Influenza Vaccines Market, by Target Group, 2019-2028 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.1.3.3 Rest of South and Central America: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 12.1.3.3.1 Overview
 - 12.1.3.3.2 Rest of South and Central America: Influenza Vaccine Market - Revenue and Forecast to 2028 (USD Million)
 - 12.1.3.3.3 Rest of South and Central America: Influenza Vaccine Market, by Vaccine Type, 2019-2028 (USD Million)
 - 12.1.3.3.4 Rest of South and Central America: Influenza Vaccine Market, by Virus Type, 2019-2028 (USD Million)
 - 12.1.3.3.5 Rest of South and Central America: Influenza Vaccine Market, by Technology, 2019-2028 (USD Million)
 - 12.1.3.3.6 Rest of South and Central America: Influenza Vaccine Market, by Route of Administration, 2019-2028 (USD Million)
 - 12.1.3.3.7 Rest of South and Central America: Influenza Vaccines Market, by Target Group, 2019-2028 (US\$ Million)
- 13. South & Central America Influenza Vaccine Market -Industry Landscape
 - 13.1 Overview
 - 13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
 - 13.3 Inorganic Growth Strategies
 - 13.3.1 Overview
 - 13.4 Organic Growth Strategies
 - 13.4.1 Overview
- 14. Company Profiles
 - 14.1 SEQIRUS
 - 14.1.1 Key Facts
 - 14.1.2 Business Description
 - 14.1.3 Products and Services
 - 14.1.4 Financial Overview
 - 14.1.5 SWOT Analysis
 - 14.1.6 Key Developments
 - 14.2 Sanofi
 - 14.2.1 Key Facts
 - 14.2.2 Business Description
 - 14.2.3 Products and Services
 - 14.2.4 Financial Overview
 - 14.2.5 SWOT Analysis
 - 14.2.6 Key Developments
 - 14.3 GlaxoSmithKline plc.
 - 14.3.1 Key Facts
 - 14.3.2 Business Description
 - 14.3.3 Products and Services
 - 14.3.4 Financial Overview
 - 14.3.5 SWOT Analysis
 - 14.3.6 Key Developments
 - 14.4 Mitsubishi Chemical Group Corporation
 - 14.4.1 Key Facts
 - 14.4.2 Business Description
 - 14.4.3 Products and Services
 - 14.4.4 Financial Overview
 - 14.4.5 SWOT Analysis
 - 14.4.6 Key Developments
 - 14.5 Serum Institute of India Pvt. Ltd
 - 14.5.1 Key Facts
 - 14.5.2 Business Description

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 MYLAN N.V.
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 AstraZeneca
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**South & Central America Influenza Vaccines Market Forecast to 2028 - COVID-19
Impact and Regional Analysis**

Market Report | 2023-01-10 | 132 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

